BR55 are promising microbubbles targeting VEGFR2, which are currently undergoing clinical trials to determine specificity and sensitivity of detection of prostate, breast and ovarian tumors angiogenesis for enhancement of contrast46. Here, KDR is linked to ovarian neoplasm.